Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer.

Publication Type:

Journal Article

Source:

Gynecologic oncology (2014)

Keywords:

2014, April 2014, Institute for Cancer Outcomes Research and Evaluation (ICORE), Public Health Sciences Division

Abstract:

Evaluate the cost-effectiveness of primary prophylaxis (PP) or secondary prophylaxis (SP) with pegfilgrastim, filgrastim (6-day and 11-day), or no prophylaxis to reduce the risk of febrile neutropenia (FN) in patients with recurrent ovarian cancer receiving docetaxel or topotecan.